Urology
Volume 69, Issue 4 , Pages 708-713 , April 2007

Serum Sex Steroid Hormones and Lower Urinary Tract Symptoms in Third National Health and Nutrition Examination Survey (NHANES III)

  • Sabine Rohrmann

      Affiliations

    • Division of Clinical Epidemiology, German Cancer Research Center, Heidelberg, Germany
    • ,
  • William G. Nelson

      Affiliations

    • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Nader Rifai

      Affiliations

    • Department of Laboratory Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Norma Kanarek

      Affiliations

    • Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    • ,
  • Shehzad Basaria

      Affiliations

    • Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Konstantinos K. Tsilidis

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    • ,
  • Ellen Smit

      Affiliations

    • Portland State University School of Community Health, Portland, Oregon
    • ,
  • Edward Giovannucci

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
    • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts
    • Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
    • ,
  • Elizabeth A. Platz

      Affiliations

    • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: Elizabeth A. Platz, Sc.D., M.P.H., Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E6138, Baltimore, MD 21205.

Received 19 July 2006 ,Accepted 5 January 2007.

References 

  1. Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology. 2002;59:877–883
  2. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479
  3. Hammarsten J, Hogstedt B, Holthuis N, et al. Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157–162
  4. Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. Arch Androl. 2000;44:213–220
  5. Andriole G, Bruchovsky N, Chung LWK, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172:1399–1403
  6. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–563
  7. Gormley GJ, Stoner E, Bruskewitz RC, et al. for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185–1191
  8. Partin AW, Oesterling JE, Epstein JI, et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145:405–409
  9. Yeh S, Miyamoto H, Shima H, et al. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci. 1998;95:5527–5532
  10. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat. 1994;1:1–407
  11. Barry MJ, Fowler FJ, O’Leary MP, et al. for the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557
  12. Food and Drug Administration: Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.fda.gov/cder/ob/. Accessed August 5, 2006.
  13. Terazosin now indicated for benign prostatic hyperplasia. Am J Hosp Pharm. 1994;51:25
  14. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672
  15. Shah BV, Barnwell BG, Bieler GS. SUDAAN User’s Manual: Software for Analysis of Correlated Data. Research Triangle Park, NC: Research Triangle Institute; 1995;
  16. Platz EA, Kawachi I, Rimm EB, et al. Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1999;2:285–289
  17. Joseph MA, Wei JT, Harlow SD, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 2002;53:322–329
  18. Monti S, Di Silverio F, Iraci R, et al. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab. 2001;86:1700–1706
  19. Norman RW, Coakes KE, Wright AS, et al. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993;150:1736–1739
  20. Castro-Magana M, Angulo M, Fuentes B, et al. Effect of finasteride on human testicular steroidogenesis. J Androl. 1996;17:516–521
  21. Suzuki K, Ito K, Ichinose Y, et al. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol. 1995;29:65–68
  22. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40–49
  23. Roberts RO, Jacobson DJ, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate. 2004;61:124–131
  24. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–944
  25. Winter ML, Liehr JG. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Toxicol Appl Pharmacol. 1996;136:211–219
  26. Smith P, Rhodes NP, Ke Y, et al. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis. 2002;5:105–110
  27. Smith P, Rhodes NP, Ke Y, et al. Relationship between upregulated oestrogen receptors and expression of growth factors in cultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone. Prostate Cancer Prostatic Dis. 2004;7:57–62
  28. Rohrmann S, Smit E, Giovannucci E, et al. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004;159:390–397
  29. Rohrmann S, Smit E, Giovannucci E, et al. Association of cigarette smoking, alcohol consumption, and physical activity with lower urinary tract symptoms in older US men—findings from the Third National Health and Nutrition Examination Survey (NHANES III). BJU Int. 2005;96:77–82

 This study is the second from the Hormone Demonstration Program, which is supported by the Maryland Cigarette Restitution Fund Research Grant Program at the Johns Hopkins University.

PII: S0090-4295(07)00012-X

doi: 10.1016/j.urology.2007.01.011

Urology
Volume 69, Issue 4 , Pages 708-713 , April 2007

Article Tools